OncoDNA signs agreement with SOLTI to provide tumor molecular profile analysis to breast cancer patients

Thursday, October 27, 2016

Belgium-based OncoDNA SA, The Cancer Theranostic Company, which supplies the only comprehensive solution from cancer profiling (OncoDEEP&TRACE), combining solid and liquid biopsies analysis to help oncologists with drug treatment options and efficacy monitoring, has signed a partnership agreement, through its Spanish distributor BioSequence, with SOLTI, a non-profit organization dedicated to clinical research in breast cancer with a broad network of leading hospital centers in Spain, Portugal, France and Italy to supply tumor molecular profiling analysis for SOLTI’s AGATA breast cancer screening program.

[Read More]